Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve 1. The Audited Financial Results of the Company for the quarter and year ended 31st March, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. To consider and approve the Directors' Report with the Annexure, Corporate Governance Report, Management Discussion and Analysis Report and Notice for convening the 32nd Annual General Meeting of the Company. 3. To consider the appointment of M/s Meenu Maheshwari & Associates, Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2025-26. 4. To consider the re-appointment of Mr. Arvind Sapkal [DIN: 08607096] for the further term of Five years as an Independent Non-Executive Director of the Company. 5. To consider the re-appointment of Internal Auditors of the Company for the year 2025-26. 6. To take on record Disclosure of Interest of Directors. 7. Any other matter with permission of the Chair.